| Literature DB >> 25821462 |
Anne Mossdorf1, Florian Ulmer1, Karsten Junge1, Christoph Heidenhain1, Marc Hein2, Ilknur Temizel3, Ulf Peter Neumann1, Wenzel Schöning1, Maximilian Schmeding1.
Abstract
Introduction. The venovenous/portal venous (VVP) bypass technique has generally become obsolete in liver transplantation (LT) today. We evaluated our experience with 163 consecutive LTs that used a VVP bypass. Patients and Methods. The liver transplant program was started in our center in 2010. LTs were performed using an extracorporal bypass device. Results. Mean operative time was 269 minutes and warm ischemic time 43 minutes. The median number of transfusion of packed cells and plasma was 7 and 14. There was no intraoperative death, and the 30-day mortality was 3%. Severe bypass-induced complications did not occur. Discussion. The introduction of a new LT program requires maximum safety measures for all of the parties involved. Both surgical and anaesthesiological management (reperfusion) can be controlled very reliably using a VVP bypass device. Particularly when using marginal grafts, this approach helps to minimise both surgical and anaesthesiological complications in terms of less volume overload, less use of vasopressive drugs, less myocardial injury, and better peripheral blood circulation. Conclusion. Based on our experiences while establishing a new liver transplantation program, we advocate the reappraisal of the extracorporeal VVP bypass.Entities:
Year: 2015 PMID: 25821462 PMCID: PMC4363615 DOI: 10.1155/2015/967951
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Recipient characteristics.
| Recipient | |
|---|---|
| Age | 54 (19–72) |
| Gender | |
| Male | 106 (65%) |
| Female | 57 (35%) |
| LabMELD | 17 (6–40) |
| LabMELD > 30 | 39 (24%) |
| Indication for LT | |
| Acute liver failure | 20 (12%) |
| Alcoholic cirrhosis | 45 (27%) |
| HCC | 40 (24%) |
| PSC | 13 (8%) |
| Graft failure | 8 (5%) |
| HBV/HCV cirrhosis | 13 (8%) |
| Others | 24 (14%) |
Donor characteristics.
| Donor | |
|---|---|
| Gender | |
| Male | 83 (51%) |
| Female | 80 (49%) |
| Age | 58 (12–86) |
| BMI | 28 (14–57) |
| CIT (min) | 459 (100–883) |
| EDC | |
|
| 27 (55.1%) |
|
| 16 (32.7%) |
|
| 5 (10.2%) |
|
| 1 (2%) |
| Age > 65 | 46 (28%) |
| BMI > 30 | 47 (28%) |
| ICU > 7 days | 29 (18%) |
| Sodium > 165 mmol/L | 5 (3%) |
| Transaminase > 150 U/L | 23 (14%) |
| Bilirubin > 3 mg/dL | 7 (4%) |
Intraoperative data.
| Transplantation | |
|---|---|
| Operation time (min) | 269 (171–594) |
| WIT (min) | 43 (20–78) |
| Rescue allocation | 77 (47%) |
| RBC | 7 (0–56) |
| FFP | 14 (1–75) |
Figure 1Postoperative creatinine values.
Figure 2Patient and graft survival.
Postoperative hospital stay and morbidity.
| Postoperative data | |
|---|---|
| Groin seroma | 2 (1%) |
| Renal failure | 18 (11%) |
| Biliary leakage | 5 (3%) |
| Thrombosis HA/PV | 3 (2%) |
| Bleeding | 28 (16%) |
| Primary nonfunction | 5 (3%) |
| Re-LT | 10 (6%) |
| ICU stay (days) | 5 (1–196) |
| Hospital stay (days) | 32 (14–299) |
Summary of current literature with comparison to our data.
| Author | Technique | Renal failure | WIT (min) | RBC ( |
|---|---|---|---|---|
|
|
|
|
|
|
|
| ||||
| Schmitz et al., 2014 [ | CR-B, | 51 | 10 | |
| CR, | 45 | 8 | ||
| PB, | 40 | 6 | ||
|
| ||||
| Sakai et al., 2010 [ | CR-B, | 35% | 43 | 9 |
| PB-B, | 25% | 30 | 9 | |
| PB, | 15% | 35 | 7 | |
|
| ||||
| Mehrabi et al., 2009 [ | PB, | 6% | 45 | 3 |
|
| ||||
|
Khan et al., 2006 [ | CR-B, | 31% | 44 | 5 |
| PB, | 25% | 43 | 4 | |
|
| ||||
| Nishida et al., 2006 [ | CR, | 45 | 18 | |
| PB, | 35 | 13 | ||
|
| ||||
| Miyamoto et al., 2004 [ | CR, | 54 | 10 | |
| PB, | 63 | 4 | ||
|
| ||||
| Cabezuelo et al., 2003 [ | CR-B, | 50% | ||
| CR, | 39% | |||
| PB, | 18% | |||
|
| ||||
| Hesse et al., 2000 [ | CR, | 24% | 20 | |
| PB, | 17% | 11 | ||
|
| ||||
| Jovine et al., 1997 [ | CR-B, | 31% | 60 | |
| PB, | 0% | 48 | ||
|
| ||||
| Cherqui et al., 1994 [ | PB, | 13% | 10 | |